Israeli biotech Pluristem Therapeutics has chosen a "leading, global" CRO to help run its Phase I blood cancer trial--but the company is a little shy on publicity, as it does not want to be named.
In a statement, Pluristem said it is pushing on with the Phase I trial of its experimental treatment using PLX-R18 cells to treat insufficient hematopoietic recovery following hematopoietic cell transplantation by "contracting with a leading global clinical research organization."
Who? Well, we can't know. Pluristem told FierceCRO that: "The CRO has a policy not to release their name in publicity by a client, so I am not able to tell you." So for now, it's a secret.
But despite not being in the press release, it will be on hand for the study, which has recently been cleared by the FDA to focus on the safety of the treatment that will consist of intramuscular injections of PLX-R18 cells in 30 patients with incomplete hematopoietic recovery persistent for 6 months or more after HCT. The trial is set to start later this year.
Pluristem Chairman and CEO Zami Aberman said: "Data from this trial will inform the potential of PLX-R18 to treat a wide range of indications including blood cancers and radiation therapy-related blood diseases."
But Aberman, not able to name names, added: "The CRO we chose has extensive experience working with leading pharmaceutical and biotech companies to successfully manage clinical trials."
- check out the release
Related Articles:
Pluristem snags spot on EMAs nascent fast-track scheme
Pluristem PLX cells turn around near fatal bone marrow failure
